Mode
Text Size
Log in / Sign up
N/A N=194 Treatment

Endurant Bifurcated and Aorto-Uni-Iliac (AUI) Stent Graft System

Abdominal Aortic Aneurysms

Enrolled (actual)
194
Serious AEs
45.9%
Results posted
Mar 2014
Primary outcome: Primary: Primary Safety Endpoint (Freedom From MAEs Within 30 Days of Index Procedure) — 88.6; 96.0 percentage of participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Endurant Stent Graft System (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Medtronic Cardiovascular
Primary completion
Sep 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Primary Safety Endpoint (Freedom From MAEs Within 30 Days of Index Procedure)
88.6; 96.0
PRIMARY
Major Adverse Events Within 30 Days of Index Procedure
11.4; 4.0; 2.3; 0; 6.8; 0.7
PRIMARY
Primary Effectiveness Endpoint (Technical Success)
43; 118
PRIMARY
Primary Effectiveness Endpoint (Treatment Success)
35; 118; 0; 0; 0; 1
SECONDARY
Secondary Endpoints - Safety Evaluation
100; 100; 97.7; 100; 86.4; 95.7
SECONDARY
Secondary Endpoint - Effectiveness Evaluation
0.0; 0.0; 100.0; 97.6; 14.3; 16.1

Summary

To demonstrate safety and effectiveness of the Endurant Stent Graft in the treatment of Abdominal Aortic or Aorto-Uni-Iliac Aneurysms.

Eligibility Criteria

Inclusion Criteria

  • Subject is ≥ 18 years old.
  • Subject (or Subject's legal representative) understands and voluntarily has signed and dated an Informed Consent document approved by the Sponsor and by the Institutional Review Board.
  • Subject is able and willing to comply with the protocol and undergo follow-up requirements.
  • Subject is a suitable candidate for elective surgical repair of AAA by as evaluated by American Society of Anesthesiologists (ASA) Physical Status Classification System I, II, III, or IV
  • Subject has an abdominal aortic or aortoiliac aneurysm characteristics that meet protocol parameter
  • Subject meets all the protocol anatomical criteria* as demonstrated on contrast-enhanced CT or MRA
  • Subject has vascular dimensions in the range of sizes available for the Endurant Stent Graft
  • Subject has documented imaging evidence of at least 1 patent iliac and 1 femoral artery, or can tolerate a vascular conduit that allows introduction of the device.
  • Subject's native vessel anatomy is more suited for the introduction and/ or deployment of an Endurant Uni-Iliac Stent Graft System.

Exclusion Criteria

  • Subject has a life expectancy < 1 year
  • Subject is participating in another investigational drug or device study
  • Subject requires emergent aneurysm treatment
  • Subject is a female of childbearing potential in whom pregnancy cannot be excluded.
  • Subject has a known hypersensitivity or contraindication to anticoagulants, antiplatelets, or contrast media, which is not amenable to pre-treatment.
  • Subject is morbidly obese (body mass index ≥ 40 kg/m2) or has other documented clinical conditions that severely inhibit radiographic visualization of the aorta.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00705718). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search